This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Mesangial Proliferative미만성 메산지움 증식성 선천성 신증후군 (미만성 mesangial 증식성 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.3 (congenital nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
C. Adult onsetLikelihood of first onset in adulthood very low — by the congenital nephrotic syndrome classification, it is a disease presenting within 3 months to 1 year after birth, and most cases are diagnosed in early infancy. Adult onset is exceptional in cases due to gene variants such as PLCE1, and early diagnosis and treatment are important for long-term prognosis.
1. History1960s: histologic classification of mesangial proliferative glomerulonephritis → PLCE1 variants identified in 2006 → genetic basis of congenital mesangial proliferative nephrotic syndrome established
2. CausesPLCE1 (phospholipase Cε1) variants are the most common cause; NPHS1 and NPHS2 variants can also be accompanied by mesangial proliferation; mesangial proliferative pattern in some WT1 variants
3. GeneticsPLCE1: AR, 10q23.33, 33 exons; partial responses to steroids/calcineurin inhibitors have been reported with PLCE1 variants, so genetic diagnosis is important
4. General epidemiologyThe mesangial proliferative type is a minority among congenital nephrotic syndromes; genetic diagnostic yield for this histologic type has improved since the discovery of PLCE1 variants
5. PathophysiologyPLCE1 protein (phospholipase Cε1) is expressed in both mesangial cells and podocytes; PLCE1 deficiency → abnormal PIP2 hydrolysis → dysfunction of mesangial cells and podocytes → proteinuria
6. SymptomsMassive proteinuria, generalized edema, hypoalbuminemia; hematuria possible; reduced renal function
7. SignsLight microscopy: proliferation of mesangial cells and matrix; immunofluorescence: possible mesangial IgM, IgG, C3 deposits; electron microscopy: foot process effacement
8. ScreeningUrine and serum tests in newborns with a family history; gene panel testing including PLCE1
9. DiagnosisKidney biopsy, gene panel (including PLCE1); evaluation of response after a trial of steroid treatment
10. TreatmentPartial response to cyclosporine or steroids in some with PLCE1 variants; ACE inhibitors/ARBs; kidney transplantation
11. PrognosisWith PLCE1 variants, progression to ESRD may be delayed in those with some treatment response; progression to ESRD within childhood in non-responders
12. PreventionGenetic counseling, prenatal/preimplantation genetic testing; early treatment trial
13. References10 key references (with PMID or DOI)

1. History

Diffuse mesangial proliferative glomerulonephritis is a histologic type showing a pattern of diffuse proliferation of mesangial cells and mesangial matrix on light microscopy, established as an independent category in the histologic classification of pediatric nephrotic syndrome in the 1960s–70s. It was initially described as a biopsy result for follow-up purposes in acquired nephrotic syndrome, but as this histologic pattern was increasingly identified in congenital and infantile-onset nephrotic syndrome, it began to be classified as a histologic subtype of congenital nephrotic syndrome.

The molecular genetic basis of congenital mesangial proliferative nephrotic syndrome advanced greatly in 2006 when Hinkes et al. reported that variants in the PLCE1 (phospholipase C epsilon 1) gene cause infantile-onset mesangial proliferative or FSGS-type nephrotic syndrome. PLCE1 is a signal transduction enzyme expressed in both mesangial cells and podocytes, and this discovery played a key role in establishing the pathogenesis of mesangial proliferative congenital nephrotic syndrome. Cases of partial response to cyclosporine treatment were reported in patients with confirmed PLCE1 variants, confirming that genetic diagnosis directly influences treatment choice.

It was subsequently reported that a mesangial proliferative pattern can also accompany other causative genes of congenital nephrotic syndrome, such as NPHS1, NPHS2, and WT1, showing the limitations of predicting the genetic cause from histologic findings alone. Currently, combined biopsy and gene panel testing has become standard practice for confirming mesangial proliferative congenital nephrotic syndrome as well. In Korea, the mesangial proliferative type has also been reported in pediatric nephrotic syndrome cohorts, and gene panel testing including PLCE1 variants is being applied clinically.

2. Causes

Among the causes of diffuse mesangial proliferative congenital nephrotic syndrome, the one receiving the most attention is variants in the PLCE1 (phospholipase C epsilon 1, 10q23.33) gene. PLCE1 is a signal transduction enzyme that generates IP3 (inositol 1,4,5-trisphosphate) and DAG (diacylglycerol) through hydrolysis of inositol phospholipids, and it is expressed in both mesangial cells and podocytes. PLCE1 variants are inherited in an autosomal recessive manner, and various forms have been reported, including nonsense variants, deletions, and missense variants.

NPHS1 (nephrin, 19q13.12) variants are the most common cause of congenital nephrotic syndrome, and some cases show a mesangial proliferative pattern in addition to the typical minimal change or FSGS pattern. NPHS2 (podocin, 1q25.2) variants have also been reported with mesangial proliferation in infantile-onset nephrotic syndrome. In WT1 (11p13) variants, especially Denys-Drash syndrome, diffuse mesangial sclerosis (DMS) is the characteristic histologic finding; this is a pattern distinct from mesangial proliferation, but caution is needed because the two are sometimes used interchangeably in the ICD classification system.

Variants in other podocyte-related genes such as LAMB2 (laminin β2), CD2AP, ADCK4, and COQ6 may also rarely present as nephrotic syndrome with a mesangial proliferative pattern. Non-hereditary causes include immune complex-mediated mesangial deposition due to congenital infections (CMV, syphilis, etc.), but in these cases a mixed pattern (mesangial proliferation + immune deposits) is often seen rather than pure mesangial proliferation.

3. Genetics

The mode of inheritance of PLCE1, the most important causative gene in diffuse mesangial proliferative congenital nephrotic syndrome, is autosomal recessive. The PLCE1 gene is located on the long arm of chromosome 10 (10q23.33) and consists of 33 exons. The PLCE1 protein is a large multifunctional enzyme of 2,303 amino acids containing several functional domains, including the Ras GTP-binding domain (RA domain), CDC25 domain, catalytic X and Y domains, and C2 domain.

Genotype-phenotype correlations of PLCE1 variants are partly established. Premature termination variants (nonsense, frameshift due to deletions/insertions) cause loss of protein expression and tend to be associated with more severe phenotypes. In contrast, with some missense variants, residual protein function remains, and cases with milder phenotypes or partial response to calcineurin inhibitor (cyclosporine) treatment have been reported, so confirming the genotype is important for treatment choice. In an international multicenter cohort (PodoNet) study, response to CNIs was observed in about 30–40% of patients with PLCE1 variants.

Genetic testing strategy: in SRNS presenting within the first year of life, a basic panel (NPHS1, NPHS2, WT1, LAMB2) is performed, and if negative, an expanded panel including PLCE1 or WES is performed. When a PLCE1 variant is identified, parental carrier testing and genetic counseling are carried out, and prenatal or preimplantation genetic diagnosis is offered for the next pregnancy. Currently in Korea, PLCE1 is included in NGS-based nephrotic syndrome gene panels, and ordering it is recommended when clinically suspected.

4. General epidemiology

Epidemiological data specific to the incidence of diffuse mesangial proliferative congenital nephrotic syndrome are limited. The proportion of the mesangial proliferative type among all congenital nephrotic syndromes differs by national cohort and is sometimes reported at around 10–20%. Unlike the Finnish type of congenital nephrotic syndrome (predominantly NPHS1 variants), PLCE1 variants have no specific founder variant and occur sporadically in diverse ethnic groups worldwide.

In international pediatric nephrology multicenter cohorts (PodoNet, EuroPOD, etc.), PLCE1 variants are reported to account for about 3–5% of SRNS patients, and PLCE1 variants tend to be found more often in the mesangial proliferative histologic type than in the FSGS histologic type. The younger the age of onset (under 1 year), the higher the probability of finding a gene variant, and in this age group the genetic diagnostic yield for mesangial proliferative nephrotic syndrome is reported at about 40–60%.

There are no independent prevalence data in Korea, but the gene distribution of Korean patients is gradually being identified through case reports and multicenter studies at pediatric nephrology centers. The number of patients registered under ICD-10 N04.3 based on health insurance claims data is small, and they are managed under Special Copayment Reduction code V263. Further research is needed on the relative frequency of PLCE1 and WT1 variants in Asian patients.

5. Pathophysiology

PLCE1 (phospholipase Cε1) is a signal transduction enzyme expressed in both mesangial cells and podocytes in the glomerulus; it hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate IP3 and DAG. IP3 triggers intracellular calcium release, and DAG activates protein kinase C (PKC), regulating various downstream signaling pathways. This signal transduction pathway is involved in cell proliferation, survival, migration, and differentiation.

Loss of enzyme function due to PLCE1 variants is understood to cause dysregulation of cell proliferation and matrix synthesis in mesangial cells, resulting in mesangial proliferation. At the same time, PLCE1 deficiency in podocytes causes foot process effacement and massive proteinuria through reduced podocyte survival signals, abnormal cytoskeletal rearrangement, and destabilization of the slit diaphragm complex. Ultimately, mesangial proliferation and podocyte injury progress simultaneously, presenting as a combination of mesangial proliferative glomerulonephritis + nephrotic-range proteinuria.

The mechanism by which mesangial proliferation directly causes proteinuria is debated. Increased mesangial matrix may reduce the glomerular filtration surface area, or compression of the glomerular capillaries by mesangial cell proliferation may affect filtration function. In addition, cytokines secreted by proliferating mesangial cells (TGF-β, PDGF, etc.) may damage podocytes and the glomerular basement membrane. In terms of treatment, the reason a CNI response is observed in some patients with PLCE1 variants is explained by the mechanism whereby CNIs increase synaptopodin expression in podocytes and contribute to cytoskeletal stabilization.

6. Symptoms

The symptoms of diffuse mesangial proliferative congenital nephrotic syndrome are mainly the nephrotic syndrome symptom complex presenting within a few weeks to 1 year after birth. There are no significant differences in clinical symptoms from other congenital nephrotic syndrome subtypes, and differences in histologic findings are the main point of distinction.

Nephrotic syndrome symptoms: nephrotic-range proteinuria (urine protein/creatinine ratio ≥ 2.0 mg/mg) and hypoalbuminemia (serum albumin < 2.5 g/dL) are the key findings. Generalized edema (eyelid edema, limb edema, ascites, pleural effusion) presents within a few weeks to 3 months after birth. Hyperlipidemia (elevated total cholesterol, LDL, triglycerides) accompanies it. Hematuria is more common than in minimal change disease, and microscopic hematuria may be observed due to glomerular structural abnormalities related to mesangial proliferation.

Reduced renal function: depending on the degree of mesangial proliferation and podocyte injury, reduced renal function may appear early at diagnosis or during the course. Elevated blood pressure also sometimes accompanies the mesangial proliferative type. Most cases are steroid-resistant (SRNS), but in some types of PLCE1 variants, partial response to cyclosporine treatment reduces proteinuria. Poorly controlled edema, infections (peritonitis, sepsis), and thrombosis (renal vein thrombosis, pulmonary embolism) are important complications. Growth retardation and malnutrition also appear, as in other congenital nephrotic syndrome subtypes.

7. Signs

On physical examination, generalized edema (eyelids, limbs, abdomen), ascites, and pleural effusion are observed, and elevated blood pressure may accompany them. Failure to thrive is observed, and muscle loss with a cachexia-like pattern appears in severe cases.

Laboratory findings: urine proteinuria (4+ dipstick), microscopic hematuria (2–3+ or RBC > 5/HPF). Low serum albumin (< 2.5 g/dL), hyperlipidemia (total cholesterol > 200 mg/dL, LDL > 130 mg/dL, elevated TG). Elevated serum creatinine and BUN (with reduced renal function). Complement (C3, C4): usually normal but may be low with immune complexes. CBC: possible anemia, platelets normal or increased (hypercoagulable state).

Kidney biopsy findings: diffuse proliferation of mesangial cells and mesangial matrix on light microscopy is characteristic. An increased number of mesangial cells per glomerulus (normal: 3–4 per glomerular section) and mesangial matrix expansion are observed. Abnormalities of the tubules, interstitium, and vessels are minimal early on. Granular deposits of IgM, IgG, or C3 in the mesangial area may appear on immunofluorescence, but it is often negative when congenital infection has been excluded. Electron microscopy confirms extensive effacement of podocyte foot processes and mesangial electron-dense deposits. It must be distinguished histologically from diffuse mesangial sclerosis (DMS) associated with WT1 variants (in DMS, matrix proliferation and sclerosis are prominent).

8. Screening

Universal screening of the general population is not performed. A screening approach is used in high-risk groups and clinically suspected cases.

Screening within high-risk families: newborns of parents who are PLCE1 variant carriers (autosomal recessive families) undergo urine protein testing and measurement of serum albumin and serum creatinine immediately after birth, and molecular genetic analysis of the familial variant confirms early whether they are affected. The same approach as for NPHS1 and NPHS2 carrier families applies.

Clinical suspicion: when SRNS is confirmed in nephrotic syndrome presenting within the first year of life, gene panel testing including PLCE1 is indicated. Especially in infants in whom a mesangial proliferative pattern is confirmed on biopsy, PLCE1 gene analysis is recommended as a priority.

Gene panel screening: in current practice, early NGS-based nephrotic syndrome gene panel testing, alongside or before biopsy, is recommended. A panel including PLCE1, NPHS1, NPHS2, WT1, and LAMB2 is standard, and identification of a PLCE1 variant is directly reflected in the treatment strategy (CNI trial). If the panel is negative, it is expanded to WES to try to discover novel gene variants.

9. Diagnosis

The diagnosis of diffuse mesangial proliferative congenital nephrotic syndrome is established by the clinical criteria for nephrotic syndrome together with kidney biopsy (confirmation of the mesangial proliferative pattern) and gene panel testing.

Clinical criteria: nephrotic syndrome presenting between 3 months and 1 year after birth (UPCR ≥ 2.0 mg/mg, serum albumin < 2.5 g/dL, edema); most cases are SRNS with no response after 4 weeks of steroid treatment. A trial of steroid treatment is also performed for diagnostic purposes when no gene variant has been identified.

Kidney biopsy: the criteria for the N04.3 classification are diffuse proliferation of mesangial cells and matrix on light microscopy (in > 50% of glomeruli) with only mild tubulointerstitial abnormalities early on. The degree of mesangial proliferation is quantified with Masson trichrome and PAS stains. Immunofluorescence and electron microscopy confirm the presence or absence of immune complex deposits and podocyte changes. Differentiation from WT1-associated diffuse mesangial sclerosis is important.

Genetic testing: because confirmation of a PLCE1 variant directly affects treatment choice (CNI trial), it is performed early alongside biopsy. An expanded nephrotic syndrome gene panel including PLCE1 or WES is recommended. When a PLCE1 variant is identified, the possibility of treatment response (30–40% partial or complete remission) is explained to the caregivers and CNI treatment is tried. When a WT1 gene variant is confirmed, evaluation for Denys-Drash and Frasier syndromes (genital abnormality examination, abdominal ultrasound, karyotyping) is performed.

10. Treatment

Treatment of diffuse mesangial proliferative congenital nephrotic syndrome is individualized according to the type of gene variant. When a PLCE1 variant is confirmed, a trial of CNI treatment is particularly important.

Steroid treatment: when no gene variant is identified or the variant is a VUS, 4 weeks of prednisolone 60 mg/m²/day is tried first. Most cases are SRNS, but if there is a response, the standard protocol is followed.

Calcineurin inhibitors (CNI): when a PLCE1 variant is confirmed, even with SRNS, cyclosporine (target trough C0 80–120 ng/mL) or tacrolimus (C0 4–8 ng/mL) is given for at least 6 months to assess the effect on proteinuria reduction. In international cohorts, partial or complete remission after CNI treatment has been reported in about 30–40% of patients with PLCE1 variants. Monitoring for long-term nephrotoxicity (serum creatinine, renal tissue fibrosis) is essential.

ACE inhibitors/ARBs, supportive care: ACE inhibitors/ARBs are given early in all patients to suppress proteinuria and preserve renal function. Edema control with intravenous albumin and diuretics, nutritional support, infection prevention (prophylactic antibiotics, vaccines), and thrombosis prevention are the core of conservative treatment.

Kidney transplantation: when the disease progresses to ESRD without response to CNI treatment, kidney transplantation is the definitive treatment. The risk of post-transplant recurrence is low when a hereditary cause is confirmed. Intensive nutritional support to reach a body weight of 8–10 kg before transplantation is the goal of pre-transplant management.

11. Prognosis

The prognosis of diffuse mesangial proliferative congenital nephrotic syndrome differs according to the type of gene variant and treatment response. When a CNI response is confirmed with PLCE1 variants, remission of proteinuria and preservation of renal function are possible to some extent, which is a relatively favorable aspect compared with other hereditary congenital nephrotic syndromes.

CNI responders: among patients with PLCE1 variants in whom a CNI response is confirmed, the rate of renal function decline slows along with remission of proteinuria, and the period of preservation before kidney transplantation is extended. Cases have been reported in which progression to ESRD was delayed by several years to more than a decade when complete remission was achieved.

CNI non-responders: patients with PLCE1 variants who do not respond to CNIs, or with NPHS1 or NPHS2 variants, progress to ESRD within childhood, similar to other hereditary congenital nephrotic syndromes. Recurrence after kidney transplantation is rare (< 10%), and transplant outcomes are good, similar to general pediatric kidney transplantation.

Denys-Drash syndrome (WT1 variants): when a DMS pattern is confirmed, the risk of Wilms tumor is very high (up to 90%), so regular surveillance and prophylactic nephrectomy are required. Progression from DMS to ESRD is rapid, and treatment of Wilms tumor must precede transplantation. Management of disorders of sex development (Frasier syndrome) after transplantation is also required.

Long-term follow-up: renal function (GFR), blood pressure, proteinuria, growth, and renal histologic changes (before transplantation) are monitored regularly. After transplantation, immunosuppression-related infections, malignancies, and graft function are followed.

12. Prevention

Prevention of diffuse mesangial proliferative congenital nephrotic syndrome consists of genetic counseling, prenatal/preimplantation genetic testing, prevention of complications, and early therapeutic intervention.

Genetic counseling and prenatal diagnosis: in families where the parents are PLCE1 variant carriers, prenatal genetic diagnosis by chorionic villus sampling or amniocentesis, or preimplantation genetic testing (PGT), is offered for the next pregnancy. It is clearly explained that the recurrence risk is 25% under AR inheritance. Genetic counseling is nondirective and supports the parents' autonomous decisions.

Early PLCE1 diagnosis and initiation of CNI treatment: in newborns and infants with confirmed PLCE1 variants, starting CNI treatment early to attempt remission of proteinuria is the most effective secondary prevention for long-term preservation of renal function. Confirmation of baseline renal function before starting CNI treatment and regular nephrotoxicity monitoring are essential.

Prevention of complications: infectious complications are minimized with pneumococcal vaccination (PCV13, PPSV23), influenza vaccination, and prophylactic penicillin (6 months to 5 years). When hypoalbuminemia persists, anticoagulation therapy is considered to prevent thrombosis. Intensive nutritional support aims to reach a body weight suitable for transplantation.


13. References

  1. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397-1405. DOI: 10.1038/ng1918. PMID: 17086183.
  2. Gbadegesin R, Hinkes B, Vlangos C, et al. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant. 2008;23(4):1291-1297. DOI: 10.1093/ndt/gfm759. PMID: 18039637.
  3. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289. DOI: 10.1681/ASN.2014050489. PMID: 25349199.
  4. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  5. Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein — nephrin — is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575-582. DOI: 10.1016/S1097-2765(00)80057-X. PMID: 9660941.
  6. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24(4):349-354. DOI: 10.1038/74166. PMID: 10742096.
  7. Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2121-2128. DOI: 10.1007/s00467-007-0633-9. PMID: 17968594.
  8. Machuca E, Benoit G, Antignac C. Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Hum Mol Genet. 2009;18(R2):R185-R194. DOI: 10.1093/hmg/ddp328. PMID: 19808799.
  9. Holmberg C, Jalanko H. Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation. Pediatr Nephrol. 2014;29(12):2309-2317. DOI: 10.1007/s00467-013-2459-8. PMID: 23793713.
  10. Kim JH, Han KH, Lee JM, et al. Genetic and clinical characteristics of childhood-onset nephrotic syndrome in Korea. J Korean Med Sci. 2019;34(6):e55. DOI: 10.3346/jkms.2019.34.e55. PMID: 30799572.